Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

Autor: Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados, Ian Marshall, Bhavana Solanky, Rebecca S Samson, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Sharmilee Gnanapavan, Gavin Giovannoni, Claudia AM Gandini Wheeler-Kingshott, Clive Hawkins, Basil Sharrack, Roger Bastow, Christopher J Weir, Nigel Stallard, Siddharthan Chandran, Jeremy Chataway

Publikováno v: Efficacy and Mechanism Evaluation, Vol 7, Iss 3 (2020)

Background: Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and riluzole are repurposed drugs with potential neuroprotective effects. Obje

Externí odkaz: https://doaj.org/article/1bf07b99cbbe44a4b0f26520d86e3ec8

HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis

Autor: Wallace J Brownlee, Carmen Tur, Andreea Manole, Arman Eshaghi, Ferran Prados, Katherine A Miszkiel, Claudia AM Gandini Wheeler-Kingshott, Henry Houlden, Olga Ciccarelli

Publikováno v: Multiple Sclerosis Journal. 29:333-342

Background: Whether genetic factors influence the long-term course of multiple sclerosis (MS) is unresolved. Objective: To determine the influence of HLA-DRB1*1501 on long-term disease course in a homogeneous cohort of clinically isolated syndrome (C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dba6f999eb7e4f305ea355264039e434
https://doi.org/10.1177/13524585221130941

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis : the MS-SMART four-arm RCT

Autor: David G. MacManus, Basil Sharrack, Gavin Giovannoni, Ferran Prados, Moira Ross, Marie Braisher, Nevin John, Nigel Stallard, Richard A Parker, Christopher J. Weir, Ian Marshall, Domenico Plantone, S Pavitt, Bhavana Solanky, Jonathan Stutters, Frederik Barkhof, Floriana De Angelis, Sebastien Ourselin, Gina Cranswick, Sharmilee Gnanapavan, Peter Connick, Anisha Doshi, Roger Bastow, Siddharthan Chandran, Rebecca S. Samson, Claudia Am Gandini Wheeler-Kingshott, Jeremy Chataway, Clive Hawkins

Publikováno v: De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados, F, Marshall, I, Solanky, B, Samson, R S, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Gnanapavan, S, Giovannoni, G, Wheeler-kingshott, C A G, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & Chataway, J 2020, ' Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT ', Efficacy and Mechanism Evaluation, vol. 7, no. 3, pp. 1-72 . https://doi.org/10.3310/eme07030
Efficacy and Mechanism Evaluation, Vol 7, Iss 3 (2020)

Background Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and riluzole are repurposed drugs with potential neuroprotective effects. Objec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4231c61f2638b7a4ede3748e11f915c2
http://wrap.warwick.ac.uk/137958/1/WRAP-Amiloride-fluoxetine-riluzole-brain-multiple-sclerosis-RCT-Stallard-2020.pdf

Clinical relevance of cortical network dynamics in early primary progressive MS

Autor: Olga Ciccarelli, Carmen Tur, Claudia Am Gandini Wheeler-Kingshott, Z Khaleeli, Sebastian Ourselin, Ferran Prados, Ahmed T. Toosy, Baris Kanber, Daniel R. Altmann, Arman Eshaghi, Alan J. Thompson

Background: Structural cortical networks (SCNs) reflect the covariance between the cortical thickness of different brain regions, which may share common functions and a common developmental evolution. SCNs appear abnormal in neurodegenerative conditi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d9c84d8ad703c53413b5d52546e9f5
https://researchonline.lshtm.ac.uk/id/eprint/4653779/1/Tur_etal_2019_Clinical_relevance_oF_cortical_network_dynamics.pdf

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab

Autor: Joanne L. Jones, Declan T. Chard, Arman Eshaghi, Alasdair Coles, M Pardini, Claudia Am Gandini Wheeler-Kingshott, J William L Brown, Ferran Prados Carrasco, Rebecca S. Samson, Tom Button, Sebastien Ourselin, Carole H. Sudre

Background: In multiple sclerosis (MS), disease effects on magnetisation transfer ratio (MTR) increase towards the ventricles. This periventricular gradient is evident shortly after first symptoms and is independent of white matter lesions. Objective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93ed7799bd3b31476ccf70e3a27276c
http://hdl.handle.net/11567/962589